Regenerative medicine company AIVITA Biomedical said on Friday that the Japanese regulatory agency, Pharmaceutical and Medical Devices Agency (PMDA), has approved and validated its manufacturing, quality and safety data for the commercialisation of its ROOT OF CANCER programme.
Following the PMDA approval, the company will now move forward to focus on the clinical protocol to obtain conditional approval to market its product in Japan.
The company's ROOT OF CANCER programme utilises autologous dendritic cells loaded with autologous antigens from the patient's tumor-initiating cells. The treatment is applicable to most solid tumor types.
Previously, the ROOT OF CANCER treatment was earlier tested in two Phase 2 trials in patients with advanced melanoma and approved for Phase 3 testing. The first Phase 2 trial demonstrated a 72% 2-year survival rate and a 54% 5-year survival rate. The second randomized Phase 2 trial demonstrated similar results, with a longer median survival, added the company.
Through its ROOT OF CANCER technology, the company said itwill now focus on advanced ovarian cancer and newly diagnosed glioblastoma in the US. Its ovarian Phase 2 double-blind study is active and enrolling 99 patients who will be randomized in a 2:1 ratio to receive either the autologous dendritic cell vaccine or autologous monocytes as a comparator. Its glioblastoma Phase 2 single-arm study is active and will enroll 55 patients to receive the treatment candidate.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study